PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study

BACKGROUND: Nivolumab and pembrolizumab were approved as immune checkpoint inhibitors for third-line treatment of advanced gastric or esophagogastric junction cancer (GC/EGJC) in 2017. However, immunotherapy monotherapy has low efficacy. Apatinib has been proven effective in advanced GC/EGJC. Numero...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qing, Yuan, Xing, Li, Jingjing, Xu, Qi, Ying, Jieer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798944/
https://www.ncbi.nlm.nih.gov/pubmed/35117897
http://dx.doi.org/10.21037/tcr-20-1333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798944/
https://www.ncbi.nlm.nih.gov/pubmed/35117897
http://dx.doi.org/10.21037/tcr-20-1333

Ejemplares similares